Investment Management

Cowen Investment Management is the Investment Management division of Cowen. We aim to build on Cowen’s core insights by developing differentiated, actively managed strategies that seek to meet the dynamic needs of our clients

Cowen Investment Management delivers differentiated strategies to a diverse client base of sophisticated investors including institutions, corporations, pension plans, sovereign wealth funds, foundations and endowments, multi-family offices and high net worth individuals.

We seek to pursue strategies that are focused in areas in which Cowen has an existing knowledge base and aim to align with Cowen’s ESG mission. Directly and through its related advisors, we offer strategies in Healthcare and Life Sciences, Sustainable Investments, Healthcare Royalties, Merger Arbitrage, and Activism. 

Cowen Investment Management is a signatory to the UN Principles of Responsible Investment (UNPRI).

Investment management professionals and clients around a conference room table

Leading with Vision

Cowen Healthcare Investments (CHI)

Cowen Healthcare Investments (CHI) makes mid-to-late stage investments into innovative private biopharmaceutical and healthcare companies. Cowen began investing in this strategy in 2012. 

Meet Our CHI Team

Latest CHI News
News

Prometheus Biosciences Announces $130 Million Financing to Advance Precision Medicines for the Treatment of Inflammatory Bowel Disease

Read the article “Prometheus Biosciences Announces $130 Million Financing to Advance Precision Medicines for the Treatment of Inflammatory Bowel Disease”
News

VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases

Read the article “VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases”
News

Escient Pharmaceuticals Raises $77.5 Million Series B Round And Initiates A Phase 1/1b Clinical Trial Of EP547, A MRGPR-Targeted Therapy To Treat Cholestatic And Uremic Pruritus

Read the article “Escient Pharmaceuticals Raises $77.5 Million Series B Round And Initiates A Phase 1/1b Clinical Trial Of EP547, A MRGPR-Targeted Therapy To Treat Cholestatic And Uremic Pruritus”
News

Freeline Closes $120 Million Series C Financing Round

Read the article “Freeline Closes $120 Million Series C Financing Round”
News

Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private Placement

Read the article “Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private Placement”
News

Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders

Read the article “Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders”
News

Cullinan Oncology Completes $98.5 Million Series B Financing

Read the article “Cullinan Oncology Completes $98.5 Million Series B Financing”
News

NodThera Announces Close of $55 Million Series B Financing

Read the article “NodThera Announces Close of $55 Million Series B Financing”
CHI Portfolio
  • Prometheus
  • F2G
  • Escient
  • Freeline
  • Nodthera
  • Autobahn
  • Keros Therapeutics
  • Larimar Therapeutics
  • Akouos
  • VectivBio
  • AM Pharma
  • Cullinan Oncology
  • Oncorus
  • Repare Therapeutics
  • Concentric Analgesics
  • Inozyme Pharma
  • KSQ
  • Evox Therapeutics
  • Therachon*
  • Pliant Therapeutics
  • Cadent Therapeutics
  • Precision Biosciences
  • Semma Therapeutics*
  • Orchard Therapeutics
  • Kezar Life Sciences
  • Compass Therapeutics
  • Livongo
  • G1 Therapeutics
  • True North Therapeutics*
  • Audentes
  • Corvus Pharmaceuticals
  • Ovid Therapeutics
  • Editas Medicine
  • Unum Therapeutics*
  • MykoKardia
  • Aeglea Biotherapeutics
  • KemPharma Inc
  • Global Blood Therapeutics
  • American Well
  • Naurex Inc*
  • Blueprint Medicine
  • Avalanche Biotech*
  • Ultra Genyx Pharmaceuticals
  • Bluebirdbio
  • GBT

*CHI Portfolio Companies with an asterisk have been acquired and/or experienced a name change; the link provided is directed to each company’s current website.

Cowen Sustainable Investments (CSI)

Founded in 2018, Cowen Sustainable Investments (CSI) provides tailored financing and data analytics solutions to companies that are accelerating the world’s transition to an environmentally sustainable economy by addressing pollution, waste, and resource constraints. 

With a focus on companies of proven technologies and products that can be enhanced with data analytics resources as well as strong management teams, the investment themes pursued by CSI include clean transportation, sustainable food production, industrial efficiency as well as renewables and storage.

Meet Our CSI Team

Latest CSI News
News

Proterra Secures $200 Million Investment from Cowen Sustainable Advisors, Soros Fund Management, Generation Investment Management, and Broadscale Group

Read the article “Proterra Secures $200 Million Investment from Cowen Sustainable Advisors, Soros Fund Management, Generation Investment Management, and Broadscale Group”
News

ecoATM Announces Investment by Cowen Sustainable Advisors

Read the article “ecoATM Announces Investment by Cowen Sustainable Advisors”
CSI Portfolio
  • ecoATM
  • Proterra

Healthcare Royalty Partners (HCR)

Founded in 2006, HealthCare Royalty Partners (HCR) is an investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage biopharmaceutical assets.

Learn more about Healthcare Royalty Partners.

Ramius Advisors

Ramius is a focused and fundamentally research-driven merger arbitrage strategy.  The current Ramius merger arbitrage team has managed merger arbitrage strategies since 2011.

Meet Our Ramius Team

Starboard Value

Starboard Value is a New York-based investment adviser with a focused and fundamental approach to investing in publicly-traded US companies. Starboard invests in deeply undervalued companies and actively engages with management teams and boards of directors to identify and execute on opportunities to unlock value for the benefit of all shareholders.

Starboard’s principals have managed investments in this manner since 2002. 

Learn more about Starboard Value.

Investment Management Team

Our team of dedicated investment professionals seek to capitalize on disruption and dislocation across market, geographies and sectors.

Investment management professional reviews report with a client

Start a Conversation

Get in touch with our Investment Management team to discuss Cowen’s Investment Management capabilities.